ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "glucocorticoids"

  • Abstract Number: 2057 • 2012 ACR/ARHP Annual Meeting

    Analysis of the Adherence to the Monitoring of Glucocorticoid Eye Toxicity and of the Prevalence of Cataracts and Glaucoma Among Patients with Systemic Lupus Erythematosus

    Linda Carli1, Chiari Tani1, Francesca Querci2, Alessandra Della Rossa1, Sabrina Vagnani3, Anna d'Ascanio4, Rossella Neri5, Antonio Tavoni6, Stefano Bombardieri3 and Marta Mosca1, 1Internal Medicine, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, 2Rheumatology Unit, University of Pisa, Pisa, Italy, 3Department of Internal Medicine, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, 4Department of Internal Medicine, University of Pisa, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, 5University of Pisa, Rheumatology Unit, Pisa, Italy, 6Dept of Internal Medicine, Immunoallergology Unit, Department of Internal Meicine, University of Pisa, PISA, Italy

    Background/Purpose: Cataracts and glaucoma are among the main causes of impaired visual acuity and have a prevalence respectively of 9-17%  and 1-2% among subjects older…
  • Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting

    Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?

    Marlies C. van der Goes1, Johannes W.G. Jacobs1, Maud S. Jurgens1, Marije F. Bakker1, Maaike J. van der Veen2, Jacobine H. van der Werf3, Paco M.J. Welsing1 and Johannes W.J. Bijlsma1, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology, St. Jansdal hospital, Harderwijk, Netherlands, 3Rheumatology, Diakonessenhuis, Utrecht, Netherlands

    Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…
  • Abstract Number: 1972 • 2012 ACR/ARHP Annual Meeting

    Assessment of Fracture Risk in Postmenopausal Women with Rheumatoid Arthritis

    Sina Esmaeilzadeh, Nurten Eskiyurt, Ekin Sen and Merih Akpinar, Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

    Background/Purpose: The aim of this study is to determine the risk of osteoporotic fracture in postmenopausal women with rheumatoid arthritis (RA) and to examine the…
  • Abstract Number: 1978 • 2012 ACR/ARHP Annual Meeting

    A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids

    Amy H. Warriner1, Ryan C. Outman2, Nathan Markward3, Ronald Aubert3, Jeffrey R. Curtis4, Robert Epstein3, Felix Freuh3, Julia McEachern3, David T. Redden5, Monika M. Safford2, Eric Stanek3, Amy Steinkellner3 and Kenneth G. Saag6, 1Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, 2Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Medco, Bethesda, MD, 4Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, 5Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 6Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL

    Background/Purpose: Despite a significant associated fracture risk, previous population-based studies document low osteoporosis treatment rates for individuals treated with chronic glucocorticoids (GCs) at risk for…
  • Abstract Number: 1946 • 2012 ACR/ARHP Annual Meeting

    Effect of Immunosuppressive Treatment On Gene Expression in Patients with Polymyositis and Dermatomyositis

    Ingela M. Loell1, Yi-Wen Chen2, Marina Korotkova3, Kanneboyina Nagaraju2 and Ingrid E. Lundberg4, 1Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 2Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, 3Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) muscle tissue is characterized by infiltrating T cells, macrophages and dendritic cells, as well as cytokines and chemokines. In…
  • Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting

    Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone

    Tim Pottel1, Christoph Schäfer2 and Gernot Keyßer2, 1Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, 2Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany

    Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
  • Abstract Number: 1241 • 2012 ACR/ARHP Annual Meeting

    Glucocorticoid use Is associated with increase in HDL in Rheumatoid Arthritis Patients

    Lisa L. Schroeder1, Xiaoqin Tang2, Mary Chester M. Wasko3 and Androniki Bili4, 1Rheumatology, Geisinger Health System, Danville, PA, 2Biostatistics, Geisinger Center for Health Research, Danville, PA, 3West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, 4Rheumatology, Geisinger Medical Center, Danville, PA

     Glucocorticoid use is associated with increase in HDL in Rheumatoid Arthritis PatientsBackground/Purpose: Atherogenic lipid profiles are common in active RA, with most common being decreased…
  • Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting

    Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists

    Jennifer E. Weiss1, Esi M. Morgan DeWitt2, Timothy Beukelman3, Laura E. Schanberg4, Rayfel Schneider5 and Yukiko Kimura6, 1Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, 2Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Pediatrics, Duke University Medical Center, Durham, NC, 5Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, 6Pediatric Rheumatology, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ

    Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…
  • Abstract Number: 469 • 2012 ACR/ARHP Annual Meeting

    Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses From the Behandelstrategiën Study

    E. Gvozdenovic1, L. Dirven1, M. van den Broek2, Kh Han3, T.H.E. Molenaar4, R. Landewe5, W.F. Lems6 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Maasstad hospital, Rotterdam, Netherlands, 4Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 5Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 6Rheumatology, VU University medical center, Amsterdam, Netherlands

    Background/Purpose: Intra articular (IA) corticosteroid injections aim at amelioration of symptoms of local inflammation in rheumatoid arthritis (RA). Some patients also report a systemic effect.…
  • Abstract Number: 389 • 2012 ACR/ARHP Annual Meeting

    Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis

    Stephen Johnston1, Tripthi Kamath2, Nianwen Shi3, Robert Fowler3, Bong-Chul Chu3 and William Reiss4, 1Truven Health Analytics, Bethesda, MD, 2Genentech, South San Francisco, CA, 3Truven Health Analytics, Washington, DC, 4Genentech Inc., South San Francisco, CA

    Background/Purpose: The current treatment paradigm in RA is to attempt to decrease concomitant use of oral glucocorticoids (OGC). This study examined the OGC-sparing effects of…
  • Abstract Number: 367 • 2012 ACR/ARHP Annual Meeting

    Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis

    Rieke Alten1, Amy Grahn2, Patricia Rice3 and Frank Buttgereit4, 1Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, 2Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 3Statistics, CliniRx Research, Naperville, IL, 4Charité - Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology